+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 6 Actively Recruiting clinical trials

O

Actively Recruiting

Researchers are evaluating the real-world effectiveness, safety, and patient compliance of ribociclib combined with an aromatase inhibitor for adjuvant treatment in patients with hormone receptor-positive, HER2-negative early breast cancer at high risk of recurrence. This observational study also compares ribociclib treatment with abemaciclib plus endocrine therapy and endocrine therapy alone, aiming to better understand treatment decisions and clinical adoption in routine practice. The study is conducted across breast centers and gynecological practices to represent typical healthcare settings. Participants receive treatment based on their physicians clinical judgment without randomization or intervention assignment. The study collects data from patients treated with ribociclib plus aromatase inhibitor with or without luteinizing hormone-releasing hormone LHRH, abemaciclib plus endocrine therapy with or without LHRH, or endocrine therapy alone with or without LHRH. Baseline data and follow-up information on adverse events, quality of life, treatment adherence, and socio-economic factors are gathered over time. During the study, participants undergo assessments including evaluation of invasive disease-free survival up to 36 months, quality of life questionnaires, medication adherence reports, and monitoring of adverse events and treatment changes. Data on reasons for treatment decisions, patient perceptions, and healthcare provider involvement are also collected. The study duration extends up to 39 months to provide a comprehensive overview of treatment impact and patient experience in real-world clinical settings.

Age: 18Years - 100YearsAll Genders
287 locations
N

Actively Recruiting

Researchers are evaluating how well asciminib works in patients with Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase Ph CML-CP. The study includes adults who are either newly diagnosed or have previously been treated with one ATP-competitive tyrosine kinase inhibitor TKI. The goal is to understand asciminibs real-world tolerability, safety, and effectiveness compared to other TKIs. Patients are divided into three groups those treated with asciminib who may have had prior TKI treatment, and two groups of newly diagnosed patients treated with either imatinib or second-generation TKIs like dasatinib, bosutinib, or nilotinib. Treatment decisions are made by the patients doctor as part of routine care, and the study observes patients who begin treatment within 14 days before or after enrollment. Participants will be followed through routine visits and asked to complete questionnaires about their health and treatment experience. Researchers will measure molecular responses at various time points up to 24 months, including major molecular response at 12 months. They will also track medication adherence, quality of life, work productivity, and reasons for dose changes or treatment interruptions. The study collects detailed data to assess treatment outcomes and tolerability over time.

Age: 18Years - 100YearsAll Genders
69 locations
S

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the effects of a partially hydrolyzed formula with synbiotics on infants at risk of allergy, specifically aiming to stop early signs of the allergic march such as atopic dermatitis. This study focuses on infants up to 14 days old who have a family history of allergy and seeks to assess both the efficacy and safety of this formula in improving skin barrier function. Participants will be randomly assigned to one of three groups a partially hydrolyzed formula with synbiotics, an intact protein formula without synbiotics, or a breastfed reference group not applicable in France. The study compares these feeding methods to observe their impact on skin health and allergy development during the first year of life. Throughout the study, infants will be monitored from enrollment until 12 to 13 months of age. Evaluations include measuring skin water loss, skin hydration, severity of atopic dermatitis, immune responses, microbiome analysis, and growth parameters like weight, height, and head circumference. Safety assessments and allergic manifestations will also be tracked to better understand the effects of the formulas and breastfeeding on allergy risk.

Age: 1Day - 14DaysAll GendersPhase Not Applicable
25 locations
C

Actively Recruiting

Researchers are evaluating the non-inferiority of minimally invasive radical hysterectomy compared to abdominal radical hysterectomy in patients with early-stage cervical cancer. This prospective, randomized, multicenter trial includes patients with specific cervical cancer types and stages, aiming to compare disease-free survival as the primary outcome. Secondary outcomes include overall survival, disease recurrence, quality of life, complications, and serious adverse events. Participants are randomly assigned to one of two groups the experimental arm receives laparoscopic or robot-assisted radical or simple hysterectomy, while the control arm undergoes abdominal radical or simple hysterectomy. Both arms follow guidelines for lymph node dissection or sentinel lymph node biopsy, with specific protective measures for the minimally invasive approach. Surgery type may vary depending on tumor risk according to SHAPE criteria. During the study, patients will be followed for at least five years after surgery. Assessments include survival outcomes, disease recurrence starting six months post-surgery, quality of life questionnaires, lymphatic side effects, complications, adverse events, and health care cost analysis. Monitoring will continue up to one year for complications and serious adverse events, ensuring comprehensive evaluation of treatment effects and safety over time.

Age: 18Years +FEMALEPhase Not Applicable
14 locations
N

Actively Recruiting

Researchers are studying the quality of life and safety of the fully resorbable TIGRae Matrix in women who have undergone implant-based breast reconstruction surgery after mastectomy. This observational, national, multicenter, prospective study aims to collect data on patient-reported outcomes and complications related to this surgical mesh device. Participants will have had the TIGRae Matrix used during their breast reconstruction either as primary or secondary surgery. The study monitors quality of life using the BREAST-Q questionnaire at multiple time points after surgery, including 6, 12, 24, and 36 months. It also tracks complication rates, hospital stay duration, cosmetic outcomes, and any unplanned additional surgeries over three to five years. During the study, participants will complete questionnaires about their quality of life and undergo follow-up assessments to document complications and cosmetic results. Researchers will observe outcomes for up to five years after surgery. The primary focus is on quality of life measured 12 months post-surgery, with additional long-term monitoring to ensure safety and effectiveness of the device.

Age: 18Years +FEMALE
5 locations
L

Actively Recruiting

Researchers are investigating the real-world use and effects of ovarian function suppression OFS combined with endocrine therapy in pre- and perimenopausal women with breast cancer who have low genomic risk according to MammaPrint testing. The study aims to understand differences in treatment outcomes based on menopausal status, chemotherapy use, and endocrine therapies, with a focus on adherence and quality of life over time. This observational registry will collect data to provide insights into treatment paths, outcomes, and factors influencing prognosis in these patients. Participants receive standard-of-care endocrine therapy with or without ovarian suppression and may have received chemotherapy based on clinical decisions and genomic risk assessments. The registry observes various treatment approaches in a real-world setting, including management of ovarian function, and follows patients for up to 10 years. Quality of life assessments occur regularly during the first five years, and treatment adherence is monitored throughout the study period. During the study, participants medical data including baseline characteristics, treatment details, relapse information, and quality of life questionnaires will be collected at multiple time points. Researchers will evaluate outcomes such as distant recurrence-free interval, disease-free survival, overall survival, and endocrine response over 5 to 10 years. The long-term follow-up allows for detailed monitoring of treatment adherence and correlation of genomic and clinicopathological markers with patient outcomes.

Age: 18Years - 60YearsFEMALE
71 locations